In Phase C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. - Participant eaten grapefruit or grapefruit items within three times prior to the https://abbv-744combinationtherap79135.ageeksblog.com/31062785/facts-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-revealed